Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Isogenica Ltd.. (2/6/17). "Press Release: Isogenica Announces New Licence Agreement with Maverick Therapeutics". Cambridge.

Organisations Organisation Isogenica Ltd.
  Organisation 2 Maverick Therapeutics Inc.
Products Product llamdA™ VHH single-domain antibody library
  Product 2 T cell therapy
Index term Index term Maverick Therapeutics–Isogenica: antibody library, 201702– license to family of llamdA VHH single-domain antibody libraries to Maverick
Person Person Collier, Adam (Isogenica 201702 Director of Commercial Development)
     


Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced a new licensing deal with Maverick Therapeutics, a private start-up biotechnology company utilising a proprietary T-cell engagement format for the development of novel T-cell redirection therapies.

Under the terms of the agreement, Isogenica has granted licences to its family of llamdA ™ VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products derived from these libraries. Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further commercial upfront and milestone payments.

Isogenica is a synthetic biology company focusing on the design and build of diverse antibody libraries for use in biopharmaceuticals. Partners can access an advanced camelid single-domain antibody library (llamdA ™) and will soon be able to access a state-of-the-art, fully synthetic and highly diverse human Fab library. The company uses its proprietary Colibra™ library technology to ensure that the constructs very accurately reflect its advanced library designs. Libraries can be screened in various formats, including phage and CIS-Display, a proprietary in vitro display technology which maintains the high diversity of the llamdA™ libraries through the discovery process.

Maverick, an MPM Capital portfolio company, was founded in 2016. On January 17, 2017, Maverick Therapeutics Inc., a spin-out from Harpoon Therapeutics, Inc., and Takeda Pharmaceutical Company Limited (TSE:4502) announced that they have entered an exclusive partnership to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. Maverick’s novel T-cell engagement format has the potential to eliminate the toxicity challenges inherent in the use of T-cell redirection therapy due to the expression of target antigen on normal tissue. Maverick’s therapeutic antibodies are designed to be inactive upon administration but fully active in the tumor microenvironment.

Ends -


Contact:

Sarah Brereton, Director, Limewash
T: 01223 813 560
E: sarah@limewash.co.uk

Adam Collier, Director of Commercial Development, Isogenica
T: 01223 533 680
E: adam.collier@isogenica.com


Notes to Editors


About Isogenica Limited

Isogenica licenses advanced synthetic antibody libraries and display technologies to enable its partners’ antibodies discovery activities. Isogenica was originally launched to develop and operate its proprietary cell-free, DNA-based display technology, CIS display, as a platform for the discovery of polypeptide biologics.

Following the acquisition and development of further technologies, including the Colibra™ DNA library building platform, we now offer opportunities for discovery partnerships with access to our skills and tools, including next-generation, best-in-class antibody libraries such as our camelid VHH (llamdA™), human scFv (Xab™) and Fab (4D Fab™) Systems. These libraries are available for license and screening partnerships, which together with its expertise in the screening of displayed peptide and scaffold libraries, can facilitate client’s biologics discovery needs. www.isogenica.com


About Maverick Therapeutics

Maverick, an MPM Capital portfolio company, was founded in 2016. On January 17, 2017, Maverick Therapeutics Inc., a spin-out from Harpoon Therapeutics, Inc., and Takeda Pharmaceutical Limited (TSE:4502) announced that they have entered an exclusive partnership to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. Maverick’s novel T-cell engagement format has the potential to eliminate the toxicity challenges inherent in the use of T-cell redirection therapy due to the expression of target antigen on normal tissue. Maverick’s therapeutic antibodies are designed to be inactive upon administration but fully active in the tumor microenvironment.

   
Record changed: 2017-05-27

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Isogenica Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px